The estimated Net Worth of Neil Josephson is at least $205 mil dollars as of 10 November 2022. Dr Josephson owns over 5,885 units of Zymeworks BC Inc stock worth over $204,780 and over the last 3 years he sold ZYME stock worth over $0.
Dr has made over 4 trades of the Zymeworks BC Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 5,885 units of ZYME stock worth $71,209 on 10 November 2022.
The largest trade he's ever made was exercising 5,885 units of Zymeworks BC Inc stock on 10 November 2022 worth over $71,209. On average, Dr trades about 2,396 units every 38 days since 2021. As of 10 November 2022 he still owns at least 16,924 units of Zymeworks BC Inc stock.
You can see the complete history of Dr Josephson stock trades at the bottom of the page.
Dr. Neil Josephson M.D. is the Chief Medical Officer at Zymeworks BC Inc.
Neil's mailing address filed with the SEC is C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709.
Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1, eGroup, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Zymeworks BC Inc executives and other stock owners filed with the SEC include: